In our research for our annual Community Oncology Trend Report, we survey independent community oncology practices’ perceived likelihood of joining an oncology network aggregator (eg, the US Oncology Network, OneOncology, American Oncology Network) in the next 5 years.
Survey data collected from 2021 to 2023 show that, year-over-year, independent practices rated increasingly higher likelihoods of joining a network aggregator, and the percentage of practices indicating a high likelihood of joining a network aggregator rose from 18% in 2021 to 35% in 2023 (Figure 1).
An increasingly consolidated provider market, competitive and economic advantages touted by network aggregators, and mixed perspectives on these promised benefits color the story behind whether practices want to join these network aggregators.
For more valuable insights, read our recently released 2023 Community Oncology Annual Trend Report. For further insights and musings on the oncology sector, check out our latest articles at https://www.hmpmarketaccessinsights.com/insights.
As always, please feel free to reach out with any questions or comments you may have.
As Oncology pathway programs continue to become more prominent in the marketplace, manufacturers are being challenged to assess how influential a specific pathway is.
Daniel BuchenbergerIn the final part of this 3-part podcast series, HMP Executive Vice President Lee Blansett and special guest John Hennessy—health system, provider and oncology strategist—explore emerging models for success in oncology practice economics.
Lee BlansettBispecific antibodies have emerged with great promise, but adoption has been slower than expected. This was a key topic discussed by a panel of 5 experts at the October 2024 Association for Value-Based Cancer Care (AVBCC) conference.
Chris Van Denburg